CO5271702A1 - Compuesto anticanceroso y metodo de separacion de enantiomeros utiles para sintetizar dicho compuesto - Google Patents
Compuesto anticanceroso y metodo de separacion de enantiomeros utiles para sintetizar dicho compuestoInfo
- Publication number
- CO5271702A1 CO5271702A1 CO00097877A CO00097877A CO5271702A1 CO 5271702 A1 CO5271702 A1 CO 5271702A1 CO 00097877 A CO00097877 A CO 00097877A CO 00097877 A CO00097877 A CO 00097877A CO 5271702 A1 CO5271702 A1 CO 5271702A1
- Authority
- CO
- Colombia
- Prior art keywords
- compound
- useful
- syntheate
- dynaments
- separation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 238000000926 separation method Methods 0.000 title 1
- -1 6-chloro-pyridin-3-yl Chemical group 0.000 abstract 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000011712 cell development Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
El presente invento se refiere al compuesto ( )-6-[amino-(6-cloro-piridin-3-il)-(3-metil-3H-imidazol-4-il)-metil]-4-(3-cloro-fenil)-1-ciclopropilmetil-1H-quinolein-2-ona, sales y solvatos farmacéuticamente aceptables del mismo, y profármacos del mismo, y al uso de dicho compuesto para inhibir un desarrollo celular anormal, incluyendo el cáncer, en animales mamíferos. El invento se refiere también a métodos útiles para sintetizar el susodicho compuesto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17771800P | 2000-01-21 | 2000-01-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5271702A1 true CO5271702A1 (es) | 2003-04-30 |
Family
ID=22649709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00097877A CO5271702A1 (es) | 2000-01-21 | 2000-12-27 | Compuesto anticanceroso y metodo de separacion de enantiomeros utiles para sintetizar dicho compuesto |
Country Status (17)
Country | Link |
---|---|
US (1) | US6479513B2 (es) |
EP (1) | EP1248782A1 (es) |
JP (2) | JP2003520796A (es) |
AR (1) | AR029792A1 (es) |
AU (1) | AU2001214087A1 (es) |
BR (1) | BR0016986A (es) |
CA (1) | CA2398353C (es) |
CO (1) | CO5271702A1 (es) |
GT (1) | GT200100008A (es) |
HN (1) | HN2000000266A (es) |
MX (1) | MXPA02007153A (es) |
MY (1) | MY126069A (es) |
PA (1) | PA8508101A1 (es) |
PE (1) | PE20011118A1 (es) |
SV (1) | SV2002000291A (es) |
TN (1) | TNSN01009A1 (es) |
WO (1) | WO2001053289A1 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HN2000000266A (es) * | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
ATE434615T1 (de) | 2000-11-21 | 2009-07-15 | Janssen Pharmaceutica Nv | Farnesyltransferase hemmende benzoheterocyclische derivate |
ES2260316T3 (es) | 2000-12-27 | 2006-11-01 | Janssen Pharmaceutica N.V. | Derivados de quinazolina y quinolina 4-sustituidos que inhiben la farnesil transferasa. |
WO2003006006A1 (en) * | 2001-07-09 | 2003-01-23 | The Regents Of The University Of California | Use of matrix metalloproteinase inhibitors to mitigate nerve damage |
EP1458720B1 (en) | 2001-12-19 | 2009-03-18 | Janssen Pharmaceutica N.V. | 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
WO2003080058A1 (en) | 2002-03-22 | 2003-10-02 | Janssen Pharmaceutica. N.V. | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
ES2271574T3 (es) | 2002-04-15 | 2007-04-16 | Janssen Pharmaceutica N.V. | Derivados triciclicos de quinazolina inhibidores de la farnesiltransferasa, sustituidos con imidazoles o triazoles enlazados al carbono. |
CA2510850A1 (en) * | 2002-12-19 | 2004-07-08 | Pfizer Inc. | 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
CA2561516A1 (en) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
DE602005007604D1 (de) | 2004-05-03 | 2008-07-31 | Janssen Pharmaceutica Nv | Diastereoselektive addition von lithiiertem n-methylimidazol an sulfinimine |
WO2005105784A1 (en) * | 2004-05-03 | 2005-11-10 | Janssen Pharmaceutica N.V. | Diastereoselective synthesis process for the preparation of imidazole compounds |
ES2346986T3 (es) | 2004-05-03 | 2010-10-22 | Janssen Pharmaceutica Nv | Proceso de sintesis diastereoselectiva con 6-bromo-4-(3-clorofenil)-2-methoxi-quinolina. |
MX2007001986A (es) * | 2004-08-26 | 2007-05-10 | Pfizer | Compuestos de aminoheteroarilo como inhibidores de proteina quinasa. |
CA2578066C (en) | 2004-08-26 | 2011-10-11 | Pfizer Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
WO2006021881A2 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
US20060107555A1 (en) * | 2004-11-09 | 2006-05-25 | Curtis Marc D | Universal snow plow adapter |
WO2007035744A1 (en) | 2005-09-20 | 2007-03-29 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2545919A1 (en) | 2005-12-23 | 2013-01-16 | Link Medicine Corporation | Treatment of synucleinopathies |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
AR062419A1 (es) | 2006-08-21 | 2008-11-05 | Hoffmann La Roche | Terapia tumoral con un anticuerpo anti- vegf |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
WO2010057006A1 (en) | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
EP2400985A2 (en) | 2009-02-25 | 2012-01-04 | OSI Pharmaceuticals, LLC | Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
AU2011223643A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2542893A2 (en) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
EP2702173A1 (en) | 2011-04-25 | 2014-03-05 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
CA3006743A1 (en) | 2015-12-03 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
TR199800825T2 (xx) * | 1995-12-08 | 1998-08-21 | Janssen Pharmaceutica N.V. | Farnesil protein transferini inhibe eden (imidazol-5-il) metil-2-kinolinon t�revleri. |
CA2341690C (en) | 1998-08-27 | 2007-04-17 | Pfizer Products Inc. | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents |
CZ20012910A3 (cs) * | 1999-02-11 | 2002-02-13 | Pfizer Products Inc. | Heteroarylem-substituované chinolin-2-onové deriváty pouľitelné jako protinádorové prostředky |
HN2000000266A (es) * | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
-
2000
- 2000-11-27 HN HN2000000266A patent/HN2000000266A/es unknown
- 2000-11-29 MX MXPA02007153A patent/MXPA02007153A/es active IP Right Grant
- 2000-11-29 JP JP2001553763A patent/JP2003520796A/ja active Pending
- 2000-11-29 AU AU2001214087A patent/AU2001214087A1/en not_active Abandoned
- 2000-11-29 BR BR0016986-2A patent/BR0016986A/pt not_active Application Discontinuation
- 2000-11-29 WO PCT/IB2000/001769 patent/WO2001053289A1/en not_active Application Discontinuation
- 2000-11-29 EP EP00976213A patent/EP1248782A1/en not_active Withdrawn
- 2000-11-29 CA CA002398353A patent/CA2398353C/en not_active Expired - Fee Related
- 2000-12-04 PA PA20008508101A patent/PA8508101A1/es unknown
- 2000-12-27 CO CO00097877A patent/CO5271702A1/es not_active Application Discontinuation
-
2001
- 2001-01-17 PE PE2001000041A patent/PE20011118A1/es not_active Application Discontinuation
- 2001-01-17 US US09/761,994 patent/US6479513B2/en not_active Expired - Fee Related
- 2001-01-18 GT GT200100008A patent/GT200100008A/es unknown
- 2001-01-18 AR ARP010100227A patent/AR029792A1/es unknown
- 2001-01-19 MY MYPI20010243A patent/MY126069A/en unknown
- 2001-01-19 TN TNTNSN01009A patent/TNSN01009A1/fr unknown
- 2001-01-22 SV SV2001000291A patent/SV2002000291A/es not_active Application Discontinuation
-
2007
- 2007-07-18 JP JP2007186597A patent/JP2007326868A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20011118A1 (es) | 2001-11-06 |
MXPA02007153A (es) | 2002-12-13 |
WO2001053289A1 (en) | 2001-07-26 |
US6479513B2 (en) | 2002-11-12 |
CA2398353C (en) | 2007-07-31 |
BR0016986A (pt) | 2002-10-08 |
HN2000000266A (es) | 2001-05-21 |
CA2398353A1 (en) | 2001-07-26 |
EP1248782A1 (en) | 2002-10-16 |
US20020004514A1 (en) | 2002-01-10 |
GT200100008A (es) | 2001-10-19 |
SV2002000291A (es) | 2002-07-16 |
TNSN01009A1 (fr) | 2005-11-10 |
JP2007326868A (ja) | 2007-12-20 |
AU2001214087A1 (en) | 2001-07-31 |
MY126069A (en) | 2006-09-29 |
AR029792A1 (es) | 2003-07-16 |
JP2003520796A (ja) | 2003-07-08 |
PA8508101A1 (es) | 2002-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5271702A1 (es) | Compuesto anticanceroso y metodo de separacion de enantiomeros utiles para sintetizar dicho compuesto | |
TR200102800T2 (tr) | Yeni bileşikler. | |
BG106440A (en) | Nitrogen-heterocyclic derivatives as nos inhibitors | |
CY1108271T1 (el) | Συνθεση που περιλαμβανει mx-dtpa και η χρηση της στην παραγωγη ραδιοεπισημασμενου mx-dtpa | |
HK1088597A1 (en) | Method for the production of substituted 3-aryl-butyl amine compounds | |
ATE510553T1 (de) | Beta-2-glycoprotein 1 als angiogenesehemmer | |
IL152891A0 (en) | Methods for decreasing cell proliferation based on (3r, 4r)-8-delta tetrahydrocannabinol-11-oic acids | |
TW200500339A (en) | Pyrrolidine derivatives, and process for the preparation | |
AU2002246702A1 (en) | Method of screening for gpr40 ligands | |
WO2004091504A3 (en) | Substituted quinobenzoxazine analogs | |
BR9914787A (pt) | Processo para a preparação de um composto | |
TR200001452T2 (tr) | Bifenilamidin türevleri. | |
EA200200101A1 (ru) | Получение замещенных пиперидин-4-онов | |
ES2185196T3 (es) | Un procedimiento para la preparacion de tetraazamacrociclos. | |
SG149005A1 (en) | Process for the preparation of thiazolopyrimidines | |
EP1613606A4 (en) | PROCESS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | |
UY26540A1 (es) | Compuesto anticanceroso y método de separación de enantiómeros útil para sintetizar dicho compuesto. | |
AU3324201A (en) | Tosylproline analogs as thymidylate synthase inhibitors | |
ATE196292T1 (de) | Zwischenprodukte um 2-imidazolin-5onederivate herzustellen. | |
AR027349A1 (es) | Derivados de amidas heterociclicas | |
WO2005021733A3 (en) | Methods and compositions for sirna expression | |
MY141850A (en) | Pharmaceutically active diazepanes | |
DK1684763T3 (da) | 6-Aryl-7-halogen-imidazo(1,2-a)pyrimidiner som anticancermiddel | |
ES2165512T3 (es) | Feniluracilos substituidos. | |
AU2000246281A1 (en) | Piperidine compounds and process for providing such |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |